Cerevel Therapeutics Inc. and Pfizer Inc. have jointly developed azaindole compounds acting as phosphodiesterase 4 (PDE4) inhibitors potentially useful for the treatment of psoriasis, atopic dermatitis, idiopathic pulmonary fibrosis, diabetes, sepsis, autoimmune disease, cystic fibrosis and inflammatory bowel disease, among others.
Ranok Therapeutics (Hangzhou) Co. Ltd. has prepared 4-(3,8-diazabicyclo[3.2.1]octan-3-yl)-pyrido[4,3-d]pyrimidine derivatives acting as son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12D mutant) interaction inhibitors and reported to be useful for the treatment of cancer.
Work at Neumora Therapeutics Inc. has led to the identification of new casein kinase I isoform δ (CKI-δ) inhibitors reported to be useful for the treatment of neurological disorders.
Flamingo Therapeutics BV and Ionis Pharmaceuticals Inc.’s FTX-001 (also known as FLM-7523) is a potential first-in-class antisense oligonucleotide (ASO) targeting the human metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) long noncoding RNA (lncRNA); it is being developed for the treatment of cancer.
Adicet Bio Inc. has obtained FDA clearance of its IND application to evaluate ADI-270, an armored allogeneic λδ CAR T-cell therapy candidate targeting CD70-positive cancers, for the treatment of relapsed or refractory renal cell carcinoma (RCC).
4D Molecular Therapeutics Inc. has obtained IND clearance by the FDA for 4D-175, an R100 vector-based intravitreal genetic medicine, for the treatment of patients with geographic atrophy.
RSS
